299 related articles for article (PubMed ID: 28667294)
1. 0404 inhibits hepatocellular carcinoma through a p53/miR-34a/SIRT1 positive feedback loop.
Xia C; Shui L; Lou G; Ye B; Zhu W; Wang J; Wu S; Xu X; Mao L; Xu W; Chen Z; Liu Y; Zheng M
Sci Rep; 2017 Jun; 7(1):4396. PubMed ID: 28667294
[TBL] [Abstract][Full Text] [Related]
2. P53/miR-34a/SIRT1 positive feedback loop regulates the termination of liver regeneration.
Gong J; Cong M; Wu H; Wang M; Bai H; Wang J; Que K; Zheng K; Zhang W; Yang X; Gong J; Shi H; Miao M; Yuan F
Aging (Albany NY); 2023 Mar; 15(6):1859-1877. PubMed ID: 36988541
[TBL] [Abstract][Full Text] [Related]
3. The p53/miR-34a/SIRT1 Positive Feedback Loop in Quercetin-Induced Apoptosis.
Lou G; Liu Y; Wu S; Xue J; Yang F; Fu H; Zheng M; Chen Z
Cell Physiol Biochem; 2015; 35(6):2192-202. PubMed ID: 25896587
[TBL] [Abstract][Full Text] [Related]
4. Analysis of microarrays of miR-34a and its identification of prospective target gene signature in hepatocellular carcinoma.
Ren FH; Yang H; He RQ; Lu JN; Lin XG; Liang HW; Dang YW; Feng ZB; Chen G; Luo DZ
BMC Cancer; 2018 Jan; 18(1):12. PubMed ID: 29298665
[TBL] [Abstract][Full Text] [Related]
5. MiR-34a overexpression enhances the inhibitory effect of doxorubicin on HepG2 cells.
Zheng SZ; Sun P; Wang JP; Liu Y; Gong W; Liu J
World J Gastroenterol; 2019 Jun; 25(22):2752-2762. PubMed ID: 31235998
[TBL] [Abstract][Full Text] [Related]
6. C-Myc-dependent repression of two oncogenic miRNA clusters contributes to triptolide-induced cell death in hepatocellular carcinoma cells.
Li SG; Shi QW; Yuan LY; Qin LP; Wang Y; Miao YQ; Chen Z; Ling CQ; Qin WX
J Exp Clin Cancer Res; 2018 Mar; 37(1):51. PubMed ID: 29523159
[TBL] [Abstract][Full Text] [Related]
7. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-133b inhibits hepatocellular carcinoma cell progression by targeting Sirt1.
Tian Z; Jiang H; Liu Y; Huang Y; Xiong X; Wu H; Dai X
Exp Cell Res; 2016 May; 343(2):135-147. PubMed ID: 27090017
[TBL] [Abstract][Full Text] [Related]
9. Regulation of Apoptosis by SYB in HepG2 Liver Cancer Cells is Mediated by the P53/Caspase 9 Axis.
Sharula ; Wu Z
Anticancer Agents Med Chem; 2017; 17(7):941-947. PubMed ID: 28356025
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-34a induces a senescence-like change via the down-regulation of SIRT1 and up-regulation of p53 protein in human esophageal squamous cancer cells with a wild-type p53 gene background.
Ye Z; Fang J; Dai S; Wang Y; Fu Z; Feng W; Wei Q; Huang P
Cancer Lett; 2016 Jan; 370(2):216-21. PubMed ID: 26523671
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-24 increases hepatocellular carcinoma cell metastasis and invasion by targeting p53: miR-24 targeted p53.
Chen L; Luo L; Chen W; Xu HX; Chen F; Chen LZ; Zeng WT; Chen JS; Huang XH
Biomed Pharmacother; 2016 Dec; 84():1113-1118. PubMed ID: 27780140
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-34a: a novel tumor suppressor in p53-mutant glioma cell line U251.
Luan S; Sun L; Huang F
Arch Med Res; 2010 Feb; 41(2):67-74. PubMed ID: 20470934
[TBL] [Abstract][Full Text] [Related]
13. Metformin induces microRNA-34a to downregulate the Sirt1/Pgc-1α/Nrf2 pathway, leading to increased susceptibility of wild-type p53 cancer cells to oxidative stress and therapeutic agents.
Do MT; Kim HG; Choi JH; Jeong HG
Free Radic Biol Med; 2014 Sep; 74():21-34. PubMed ID: 24970682
[TBL] [Abstract][Full Text] [Related]
14. Carbon monoxide protects against hepatic ischemia/reperfusion injury by modulating the miR-34a/SIRT1 pathway.
Kim HJ; Joe Y; Yu JK; Chen Y; Jeong SO; Mani N; Cho GJ; Pae HO; Ryter SW; Chung HT
Biochim Biophys Acta; 2015 Jul; 1852(7):1550-9. PubMed ID: 25916635
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment.
Yang F; Li QJ; Gong ZB; Zhou L; You N; Wang S; Li XL; Li JJ; An JZ; Wang DS; He Y; Dou KF
Technol Cancer Res Treat; 2014 Feb; 13(1):77-86. PubMed ID: 23862748
[TBL] [Abstract][Full Text] [Related]
16. SIRT1 regulates oncogenesis via a mutant p53-dependent pathway in hepatocellular carcinoma.
Zhang ZY; Hong D; Nam SH; Kim JM; Paik YH; Joh JW; Kwon CH; Park JB; Choi GS; Jang KY; Park CK; Kim SJ
J Hepatol; 2015 Jan; 62(1):121-30. PubMed ID: 25131770
[TBL] [Abstract][Full Text] [Related]
17. p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma.
Fornari F; Milazzo M; Galassi M; Callegari E; Veronese A; Miyaaki H; Sabbioni S; Mantovani V; Marasco E; Chieco P; Negrini M; Bolondi L; Gramantieri L
Mol Cancer Res; 2014 Feb; 12(2):203-16. PubMed ID: 24324033
[TBL] [Abstract][Full Text] [Related]
18. Effect of Tumor Suppressor MiR-34a Loaded on ZSM-5 Nanozeolite in Hepatocellular Carcinoma: In Vitro and In Vivo Approach.
Salah Z; Abd El Azeem EM; Youssef HF; Gamal-Eldeen AM; Farrag AR; El-Meliegy E; Soliman B; Elhefnawi M
Curr Gene Ther; 2019; 19(5):342-354. PubMed ID: 31701846
[TBL] [Abstract][Full Text] [Related]
19. RBM38 plays a tumor-suppressor role via stabilizing the p53-mdm2 loop function in hepatocellular carcinoma.
Ye J; Liang R; Bai T; Lin Y; Mai R; Wei M; Ye X; Li L; Wu F
J Exp Clin Cancer Res; 2018 Sep; 37(1):212. PubMed ID: 30176896
[TBL] [Abstract][Full Text] [Related]
20. [Growth inhibition of human hepatocellular carcinoma by miRNA-204 via down-regulation of Bcl-2 and Sirt1 expression].
Li K; Xyu Q; Liu X; Liu Q; Wang M
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 Feb; 31(2):168-72. PubMed ID: 25652855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
